Drug intelligence / Profile preview

XP-103

Development stage: Preclinical
Lead developer: Xynomic Pharmaceuticals Holdings
Modality: Small Molecules
Administration: Topical

Overview

**XP-103** is a small molecule dual inhibitor targeting tropomyosin receptor kinases (TRK/NTRK) and Fra-1 (Fos-related antigen 1), transcription factors involved in oncogenesis and tumor progression. Developed by Xynomic Pharmaceuticals, it is designed for oncology applications, particularly solid tumors driven by NTRK fusions or Fra-1 overexpression. The compound remains in early preclinical development, specifically the lead optimization stage, as part of Xynomic's pipeline focused on kinase inhibitors for cancer therapy.[1][3][5][7]

Targets

FOSL1 (FOS-like antigen 1)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)

Beyond the preview

Go deeper on XP-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XP-103.